Compare BMRA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | CVKD |
|---|---|---|
| Founded | 1971 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 20.7M |
| IPO Year | N/A | 2023 |
| Metric | BMRA | CVKD |
|---|---|---|
| Price | $2.37 | $8.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 21.5K | ★ 43.2K |
| Earning Date | 01-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,884,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $8.12 |
| 52 Week High | $10.16 | $22.90 |
| Indicator | BMRA | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 37.75 |
| Support Level | $2.43 | $9.55 |
| Resistance Level | $2.67 | $12.50 |
| Average True Range (ATR) | 0.12 | 1.03 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 27.06 | 16.26 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.